Amneal Announces U.S. FDA Approval of Cyclosporine Ophthalmic Emulsion 0.05%

BRIDGEWATER, N.J., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (NASDAQ: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company’s cyclosporine ophthalmic emulsion 0.05%, a sterile, preservative-free formulation supplied in single-use vials. The product is the generic equivalent of RESTASIS^® (cyclosporine ophthalmic emulsion) 0.05%, a registered trademark of Allergan, an AbbVie company.

Read more at globenewswire.com